HUE028615T2 - Oszteoartritisz kezelés - Google Patents

Oszteoartritisz kezelés Download PDF

Info

Publication number
HUE028615T2
HUE028615T2 HUE09833924A HUE09833924A HUE028615T2 HU E028615 T2 HUE028615 T2 HU E028615T2 HU E09833924 A HUE09833924 A HU E09833924A HU E09833924 A HUE09833924 A HU E09833924A HU E028615 T2 HUE028615 T2 HU E028615T2
Authority
HU
Hungary
Prior art keywords
antibody
csf
ser
seq
leu
Prior art date
Application number
HUE09833924A
Other languages
English (en)
Inventor
John Allan Hamilton
Andrew David Cook
Original Assignee
Univ Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42286786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE028615(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Melbourne filed Critical Univ Melbourne
Publication of HUE028615T2 publication Critical patent/HUE028615T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Virology (AREA)
  • Glass Compositions (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Polarising Elements (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Claims (7)

  1. Szabadalmi Igénypontok í. GM-CSFantagonists! a eszteoartrkisz kezelésében történőalkalmazásra, ahol;azantagemístaegy GM-€S Ore spéci gkos antitest
  2. 2.. Készítmény, amely tartalmazza az oszteoariritisz kszetésébéntórténó: alkalmazásba szolgáié öM-CSF antagsmsíái, áltól az amsgoméía egy GiM-CSf-m sfeciííkés aníiíesk és -afeöj á t^l^ény'íamfe^^íÉfeíl'eg^ vagy több gyógyszerészeti leg elfogadható %>fd«zót és·· vagy higltösze rt.
  3. 3. Antitest alkalmazásra az í. vagy 2. Igénypont szerint ábot: az antiütsi kimére antitest humanizált antitest vagy humán antitest.
  4. 4. Antitest alkalmazásra a 3. igét^ypons szériái, ahol az antitest bumaftizóií antitest,
  5. 5. Antitest alkalmazásra az M. Igénypontok bármelyike szerint, ahol az antitest .artaimaz. nehéz.iátte. variábilis régiót, amely: legalább fÖSk-bs® homológ a: SEQ H.) NO: 3 anriimsáy'Szekeebóiájáygl, és könnyű!ánc. variábsíis régiói, amely legalább 90%-han Immoidg teSGOID NÚ:4 $mmsav~sz$kwm:é}SV0·
  6. 6. Antitest alkalmazásra az 5, igénypont szerint, ahol az antitest tartalmaz nebéziánc variábilis régiót, amely legalább 95%-ban homológ a SEQ 10 N0:3 arntnosav-szekvenaájávai, és könnyűlánc variábilis régiói, amely legalább 95%-ban homológ a SEQ ID Nö:4 arolnösav-szekvsfieiáíával.
  7. 7., Antitest alkalínazásm az 5- igénypont szerint. ahol az snittes? Tartalmazza a SEO 10190:3 aminosav^ ;szekvendá|ö .nehézlánc variábilis régiói: és s SEQ 10190:4 asii80sav«szek:yeneiá|ó könnyűiére variábilis régiót
HUE09833924A 2008-12-22 2009-12-21 Oszteoartritisz kezelés HUE028615T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13967908P 2008-12-22 2008-12-22
US16448609P 2009-03-30 2009-03-30

Publications (1)

Publication Number Publication Date
HUE028615T2 true HUE028615T2 (hu) 2016-12-28

Family

ID=42286786

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE09833924A HUE028615T2 (hu) 2008-12-22 2009-12-21 Oszteoartritisz kezelés

Country Status (19)

Country Link
US (4) US9243061B2 (hu)
EP (2) EP2376121B2 (hu)
JP (3) JP5727379B2 (hu)
KR (2) KR101799264B1 (hu)
CN (2) CN102271705A (hu)
AU (1) AU2009329814B2 (hu)
BR (1) BRPI0918356B1 (hu)
CA (1) CA2746827C (hu)
CY (1) CY1117698T1 (hu)
DK (1) DK2376121T4 (hu)
ES (2) ES2886063T3 (hu)
HK (1) HK1226938A1 (hu)
HR (1) HRP20160577T4 (hu)
HU (1) HUE028615T2 (hu)
PL (1) PL2376121T5 (hu)
RU (2) RU2712273C2 (hu)
SI (2) SI2376121T1 (hu)
SM (1) SMT201600156B (hu)
WO (1) WO2010071924A1 (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102256621B (zh) 2008-12-22 2017-12-12 墨尔本大学 疼痛治疗
US9243061B2 (en) 2008-12-22 2016-01-26 University Of Melbourne Osteoarthritis treatment
WO2014044768A1 (en) 2012-09-20 2014-03-27 Morphosys Ag Treatment for rheumatoid arthritis
DE102013222200A1 (de) * 2013-10-31 2015-08-27 Osram Opto Semiconductors Gmbh Elektronisches Bauelement und Verfahren zum Herstellen eines elektronischen Bauelements
BR112020003025A2 (pt) * 2017-08-14 2020-08-04 Zynerba Pharmaceuticals, Inc. métodos de tratamento de osteoartrite com gel transdérmico de canabidiol
WO2020104833A1 (en) * 2018-11-19 2020-05-28 4P-Pharma Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production
CN110075304B (zh) * 2019-05-29 2020-02-11 四川大学华西医院 一种治疗骨关节炎的药物组合物及其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
HUT63181A (en) 1989-07-14 1993-07-28 Schering Corp Process for producing gm-csf antagonists originating from carboxy terminal of gm-csf
WO1991002063A1 (en) 1989-08-11 1991-02-21 Amrad Corporation Limited Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
WO1994009149A1 (en) 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
CA2149881A1 (en) 1992-11-19 1994-05-26 Paul T. Jubinsky Antibodies for gm-csf receptor and uses thereof
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
WO2003035048A2 (en) * 2001-10-26 2003-05-01 Novartis Ag Methods for the treatment of osteoarthritis and compositions thereof
ES2365606T3 (es) 2002-02-13 2011-10-07 Ludwig Institute For Cancer Research Ltd. Anticuerpos contra gm-csf quiméricos.
US20040241755A1 (en) * 2003-06-02 2004-12-02 Pfizer Inc. Human cell assay to determine effect of sample compounds on Col2 enhancer expression
ATE464908T1 (de) 2004-02-11 2010-05-15 Warner Lambert Co Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
EP1759710B1 (en) * 2004-03-31 2014-05-07 Kazuwa Nakao Remedy or preventive for arthritis
DE602004021773D1 (de) 2004-05-05 2009-08-13 Micromet Ag Herstellung eines einkettigen fv Antikörperfragments
EP1782074A2 (en) * 2004-08-18 2007-05-09 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Biomarkers for osteoarthritis
US20060040258A1 (en) 2004-08-23 2006-02-23 Huiyan Guo Water-soluble conjugates and methods of preparation
SG161292A1 (en) 2005-04-18 2010-05-27 Micromet Ag Antibody neutralizers of human granulocyte macrophage colony stimulating factor
ES2527428T3 (es) * 2005-05-18 2015-01-23 Morphosys Ag Anticuerpos anti-GM-CSF y usos de los mismos
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
CN101466734A (zh) * 2005-12-01 2009-06-24 杜门蒂斯有限公司 与白细胞介素-1受体1型结合的竞争性域抗体形式
KR101486183B1 (ko) * 2006-02-08 2015-01-28 모르포테크, 인크. 항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체
DK1999152T3 (da) 2006-03-27 2013-01-14 Medimmune Ltd Bindende element til gm-csf-receptor
US7741273B2 (en) 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
ES2432173T3 (es) * 2006-11-21 2013-12-02 Kalobios Pharmaceuticals, Inc. Métodos de tratamiento de enfermedades inflamatorias crónicas usando un antagonista de GM-CSF
WO2008080134A2 (en) * 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
CN101687926A (zh) * 2007-05-23 2010-03-31 哮喘和气道Crc有限公司 中和抗体
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
WO2009042854A1 (en) * 2007-09-26 2009-04-02 Musculoskeletal Research Llc Ion-channel regulator compositions and methods of using same
US20100297135A1 (en) 2007-11-12 2010-11-25 Crc For Asthma And Airways Ltd. Epitope for neutralizing antibodies
AR069290A1 (es) * 2007-11-13 2010-01-13 Evec Inc Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden
CN102282173A (zh) 2008-03-24 2011-12-14 艾博特生物技术有限公司 用于治疗骨丢失的方法和组合物
EP3449941A1 (en) 2008-04-28 2019-03-06 Humanigen, Inc. Antibodies to granulocyte-macrophage colony-stimulating factor
US9243061B2 (en) 2008-12-22 2016-01-26 University Of Melbourne Osteoarthritis treatment
CN102256621B (zh) 2008-12-22 2017-12-12 墨尔本大学 疼痛治疗
SG175305A1 (en) 2009-04-23 2011-11-28 Theraclone Sciences Inc Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies

Also Published As

Publication number Publication date
PL2376121T3 (pl) 2016-12-30
HRP20160577T1 (hr) 2016-07-29
CY1117698T1 (el) 2017-05-17
ES2572368T3 (es) 2016-05-31
US9243061B2 (en) 2016-01-26
SI2376121T1 (sl) 2016-07-29
JP2012512815A (ja) 2012-06-07
US20180066062A1 (en) 2018-03-08
JP6458086B2 (ja) 2019-01-23
CA2746827A1 (en) 2010-07-01
KR20110128273A (ko) 2011-11-29
RU2011127334A (ru) 2013-01-27
PL2376121T5 (pl) 2021-09-27
EP2376121A1 (en) 2011-10-19
KR20170128630A (ko) 2017-11-22
HRP20160577T4 (hr) 2021-08-20
CN102271705A (zh) 2011-12-07
JP2017200933A (ja) 2017-11-09
CN106397591A (zh) 2017-02-15
AU2009329814A1 (en) 2010-07-01
KR101799264B1 (ko) 2017-11-20
US20200247895A1 (en) 2020-08-06
JP2015143233A (ja) 2015-08-06
ES2886063T3 (es) 2021-12-16
EP2376121B2 (en) 2021-06-09
US20160185868A1 (en) 2016-06-30
EP3056217A1 (en) 2016-08-17
BRPI0918356A2 (pt) 2020-10-06
DK2376121T3 (en) 2016-05-30
EP2376121A4 (en) 2013-04-03
HK1226938A1 (zh) 2017-10-13
SMT201600156B (it) 2016-08-31
RU2016102339A3 (hu) 2019-07-29
JP5727379B2 (ja) 2015-06-03
DK2376121T4 (da) 2021-08-16
CA2746827C (en) 2018-01-23
EP3056217B1 (en) 2021-06-30
US20120003234A1 (en) 2012-01-05
WO2010071924A1 (en) 2010-07-01
RU2712273C2 (ru) 2020-01-28
EP2376121B1 (en) 2016-03-09
KR101898982B1 (ko) 2018-09-14
SI2376121T2 (sl) 2021-11-30
ES2572368T5 (es) 2021-12-16
BRPI0918356B1 (pt) 2022-03-08
AU2009329814B2 (en) 2015-06-18
RU2016102339A (ru) 2018-11-21

Similar Documents

Publication Publication Date Title
US20200247895A1 (en) Osteoarthritis treatment
US10815297B2 (en) Antagonists of IL17C for the treatment of inflammatory disorders
US10982001B2 (en) Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
EP3539984A1 (en) Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
IL266770B1 (en) Antagonist to 33-il in combination with antagonist to 4r-il for the treatment of diseases or inflammatory disorders in the airway or lungs
EP2387418B1 (en) Pain treatment
US20100239590A1 (en) Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
KR20190053184A (ko) 아토피성 피부염을 치료하기 위한 il-13 길항제의 용도
KR20170016501A (ko) 콜로니 자극 인자 1 수용체 (ｃｓｆ1ｒ)에 결합하는 항체를 이용하여 병태를 치료하는 방법
AU2015224416B2 (en) Osteoarthritis treatment
JP2017125040A (ja) コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法